Cantor Fitzgerald initiated coverage of MoonLake Immunotherapeutics (NASDAQ:MLTX) with an “overweight” rating and a 12-month price target of $23. The stock closed at $16.30 on Feb. 13. MoonLake has an IL-17A and IL-17F...
H.C. Wainwright launched coverage of OmniAb (NASDAQ:OABI) with a “buy” rating and a price target of $11. The stock closed at $3.88 on Feb. 10. At its core, OmniAb is an antibody discovery, optimization, and licensing...
Cognition Therapeutics (NASDAQ:CGTX) completed enrollment in the randomized, double-blind Phase 2 SEQUEL study of its CT1812 in 16 adults with mild-to-moderate Alzheimer’s disease. The study was designed to assess...
Abbott (NYSE:ABT) agreed to acquire Cardiovascular Systems, Inc. (NASDAQ:CSII) for $20 a share or approximately $890-million. Cardiovascular Systems is a leader in devices for atherectomy, a minimally invasive treatment...
Germany’s Federal Institute for Drugs and Medical Devices approved NeuroSense Therapeutics’ (NASDAQ:NRSN) clinical trial application to enroll patients in PARADIGM, a Phase 2b study of its lead combination drug...
Annovis Bio (NYSE:ANVS) received approval to open 48 clinical trial sits in five European Union countries for its ongoing Phase 3 study of buntanetap for the treatment of Parkinson’s disease (PD). The company is...
Dr. Dan Williams, CEO and Co-founder The FDA granted a rare pediatric disease (RPD) designation to closely-held SynaptixBio of the UK to develop the first treatment for TUBB4A leukodystrophy, a rare genetic and...
Tonix Pharmaceuticals (NASDAQ:TNXP) enrolled the first participant in the Phase 2 PREVENTION study of TNX-1900 (intranasal potentiated oxytocin) for the prevention of chronic migraine headache. The double-blind, placebo...
Cantor Fitzgerald launched coverage of Outlook Therapeutics (NASDAQ:OTLK) with an “overweight” rating and a 12-month price target of $4. The stock closed at $1.15 on Feb. 3. Outlook is a biopharmaceutical company that...
The American Urology Association has accepted for a moderated poster presentation at its annual meeting Theralase Technologies’ (TSXV:TLT; OTCQB:TLTFF) interim data from its Phase 2 Bacillus Calmette Guerin unresponsive...
Miromatrix Medical (NASDAQ:MIRO) has evaluated a clinical hold on its investigational miroliverELAP transplantable organ and plans to submit its response to the FDA in the second half of 2023 and initiate a first-in...
Roth Capital Partners completed its acquisition of MKM Partners on Jan. 31, and the combined organization will conduct business as ROTH MKM. This is the first acquisition ROTH has made in its 30-plus years of business...